MAP3K2

Across TCGA pan-cancer cohorts, MAP3K2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP3K2 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAP3K2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP3K2 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and PDAC are the cancer types where MAP3K2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.264	0.803	<.001	38	view →
LUAD	OS	Median	II,III,IV	0.329	0.913	.001	32	view →
PDAC	OS	Median	IV	0.231	0.927	.004	25	view →
HNSC	DFS	Tertile	III,IV	0.307	1.000	.016	23	view →
LSCC	DFS	Tertile	II,III,IV	0.484	0.837	.028	11	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP3K2–CCRCC (DFS)

Open the CCRCC breakdown →